Cargando…

2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital

BACKGROUND: Long-term acute care Hospital (LTACH) systematically selects a unique patient population with multiple risk factors for Carbapenem-resistant Enterobacteriaceae (CRE) colonization and infection leading to an increase CRE prevalence at these facilities. This selection bias creates a fertil...

Descripción completa

Detalles Bibliográficos
Autores principales: Dogho, Patience, Osadiaye, Nancy, Igbinosa, Osamuyimen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253670/
http://dx.doi.org/10.1093/ofid/ofy210.2071
_version_ 1783373550207369216
author Dogho, Patience
Osadiaye, Nancy
Igbinosa, Osamuyimen
author_facet Dogho, Patience
Osadiaye, Nancy
Igbinosa, Osamuyimen
author_sort Dogho, Patience
collection PubMed
description BACKGROUND: Long-term acute care Hospital (LTACH) systematically selects a unique patient population with multiple risk factors for Carbapenem-resistant Enterobacteriaceae (CRE) colonization and infection leading to an increase CRE prevalence at these facilities. This selection bias creates a fertile ground to harness scientific data and test hypothesis. We performed a retrospective analysis of patients with CRE infections diagnosed and treated in one LTACH. METHODS: Baseline data, antimicrobial treatment, and outcomes were collected in patients with bacteremia, healthcare-associated pneumonia (HCAP), and complicated urinary tract infection (cUTI)/acute pyelonephritis (AP) due to CRE diagnosed between January 2017 and December 2017. RESULTS: 57 cases of CRE infections were identified over the study period; 12 bacteremia, 20 HCAP and 25 cUTI/AP. The proportion of patient with significant comorbidities include; 31.5% diabetes, 40.4% heart failure, 29.8% kidney disease and 10% with solid tumors. 89.5% of patients presented with sepsis and 33.3% had septic shock. Among 57 patients, majority (56) received empiric antibiotics known to have activity against Gram negative but only 38.6% had in vitro activity against the CRE organism recovered from cultured specimen. 85% of index CRE isolate was Klebsiella pneumoniae, 8.7% Enterobacter cloacae, 3.5% Proteus mirabilis, and 1.8% Escherichia coli. Treatment regimen varied; however, 78.9% received monotherapy. Overall outcome was poor with 28-day mortality of 17.5% across all infection sites but up to 25% in patients with bacteremia. CONCLUSION: In this study, we report our clinical experience treating CRE infections in LTACH. We proved that CRE infections occurred in patients with substantial co-morbidities. Even though clinical outcome remain of great concern, 28-day mortality and rate of eradication of CRE in the study were comparatively better than other national estimates. Inappropriate empiric treatment may be one of the many factors leading to overall poor treatment outcomes. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253670
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62536702018-11-28 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital Dogho, Patience Osadiaye, Nancy Igbinosa, Osamuyimen Open Forum Infect Dis Abstracts BACKGROUND: Long-term acute care Hospital (LTACH) systematically selects a unique patient population with multiple risk factors for Carbapenem-resistant Enterobacteriaceae (CRE) colonization and infection leading to an increase CRE prevalence at these facilities. This selection bias creates a fertile ground to harness scientific data and test hypothesis. We performed a retrospective analysis of patients with CRE infections diagnosed and treated in one LTACH. METHODS: Baseline data, antimicrobial treatment, and outcomes were collected in patients with bacteremia, healthcare-associated pneumonia (HCAP), and complicated urinary tract infection (cUTI)/acute pyelonephritis (AP) due to CRE diagnosed between January 2017 and December 2017. RESULTS: 57 cases of CRE infections were identified over the study period; 12 bacteremia, 20 HCAP and 25 cUTI/AP. The proportion of patient with significant comorbidities include; 31.5% diabetes, 40.4% heart failure, 29.8% kidney disease and 10% with solid tumors. 89.5% of patients presented with sepsis and 33.3% had septic shock. Among 57 patients, majority (56) received empiric antibiotics known to have activity against Gram negative but only 38.6% had in vitro activity against the CRE organism recovered from cultured specimen. 85% of index CRE isolate was Klebsiella pneumoniae, 8.7% Enterobacter cloacae, 3.5% Proteus mirabilis, and 1.8% Escherichia coli. Treatment regimen varied; however, 78.9% received monotherapy. Overall outcome was poor with 28-day mortality of 17.5% across all infection sites but up to 25% in patients with bacteremia. CONCLUSION: In this study, we report our clinical experience treating CRE infections in LTACH. We proved that CRE infections occurred in patients with substantial co-morbidities. Even though clinical outcome remain of great concern, 28-day mortality and rate of eradication of CRE in the study were comparatively better than other national estimates. Inappropriate empiric treatment may be one of the many factors leading to overall poor treatment outcomes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253670/ http://dx.doi.org/10.1093/ofid/ofy210.2071 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Dogho, Patience
Osadiaye, Nancy
Igbinosa, Osamuyimen
2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title_full 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title_fullStr 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title_full_unstemmed 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title_short 2418. Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
title_sort 2418. management of carbapenem-resistant enterobacteriaceae infections in a long-term acute care hospital
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253670/
http://dx.doi.org/10.1093/ofid/ofy210.2071
work_keys_str_mv AT doghopatience 2418managementofcarbapenemresistantenterobacteriaceaeinfectionsinalongtermacutecarehospital
AT osadiayenancy 2418managementofcarbapenemresistantenterobacteriaceaeinfectionsinalongtermacutecarehospital
AT igbinosaosamuyimen 2418managementofcarbapenemresistantenterobacteriaceaeinfectionsinalongtermacutecarehospital